Merck to help make J&J's coronavirus vaccine: White House official

The deal with J&J comes just days after the US government authorized its one-dose Covid-19 vaccine and as the company looks to increase its production

Johnson & Johnson
The drugmaker expects to deliver another 16 million doses by the end of this month
Reuters
2 min read Last Updated : Mar 02 2021 | 8:32 PM IST
Merck & Co Inc will help make rival Johnson & Johnson's single-shot Covid-19 vaccine in a partnership set to be announced on Tuesday by US President Joe Biden, a White House official said on Tuesday.
 
After scrapping development of its own Covid-19 vaccine candidates in January, Merck last month said it was working on a deal to open up its manufacturing capacity to other vaccine makers.
 
The deal with J&J comes just days after the US government authorized its one-dose Covid-19 vaccine and as the company looks to increase its production. The drugmaker said on Monday it was working on signing up new manufacturing partners.
 
J&J is shipping about four million doses of its vaccine in the United States this week, but the next shipments hinge on when its new, larger manufacturing plant receives regulatory approvals.
 
The drugmaker expects to deliver another 16 million doses by the end of this month.
 
J&J's vaccine is expected to be easier to distribute because it only needs to be refrigerated, while vaccines from Pfizer Inc /BioNTech SE and Moderna Inc need to be frozen. Those vaccines also require two shots.
 
The drugmaker will dedicate two US facilities to J&J's vaccine, according to a report in the Washington Post, which first reported the news of the arrangement on Tuesday. (https://wapo.st/304E8ZQ) "Merck remains steadfast in our commitment to contribute to the global response to the pandemic," the company said.
 
J&J did not immediately respond to a Reuters request for comment.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusJohnson & Johnson'sCoronavirus TestsCoronavirus Vaccine

Next Story